Review I Flashcards Preview

RENAL II Exam 1 > Review I > Flashcards

Flashcards in Review I Deck (44):
1

IV injection

must be soluble

also, has rapid onset and control of concentration is possible

2

depot preparation

benzathine penicillin G

3

plasma Vd

4L

4

ECF Vd

14L

5

total body water Vd

42L

6

neostigmine

quaternary
no CNS effects bc permanent chargw

7

physostigmine

tertiary
goes to CNS

8

thiopental

high lipid solubility
quick to CNS, quick out

9

barriers with oral

epithelial cells
capillary wall

10

subQ

slower absorption

depot preparation

11

depot preparations

via subQ or IM

12

IM

rapid
-fast access to blood

13

excretion of weak bases

acidic urine

14

excretion of weak acids

basic urine

15

equilibrium distribution of weak acids

plasma > intracellular

16

equilibrium distribution of weak bases

intracellular > plasma

17

phenobarbitol distribution

weak acid

decrease pH - goes to tissue
increase pH - goes to plasma

18

more likely to have drug drug interaction

bound in quantity
limited Vd
slowly eliminated
low therapeutic index

19

anion transport

elimination of PCN, antibiotics, salicylates

20

cation transport

elimination of quaternary, ganglion blockers, NMJ blockers

21

morphine

affected by first pass effect big time

22

phase 1

catabolic

23

phase 2

anabolic

24

pseudocholinesterase

genetic defect - slow metabolism of succinycholine
-longer duration of paralysis

25

n-acetyltransferase

slow acetylator phenoytpe - autosomal recessive
-decreased isoniazid, hydralazine, caffeine metabolism

risk of hepatotoxicity if take isoniazid

26

inducers of P450

phenytoin
phenobarbitol
chronic alcohol
clofibrate
isoniazid

27

erythromycin

inactivate CYP3A
-competitive inhibition

28

chloramphenicol

inactivates CYP2B1
-irreversible

29

grapefruit juice

inhibit CYP3A4

30

important factor for altered drug metabolism in elderly

liver and kidney disease

31

UDP-glycosyltransferase

mutations lead to altered metabolism of camptothecin

32

camptothecin

UDP glycosyltransferase mutation alters metabolism

33

ryanodine receptors

mutations lead to malignant hyperthermia
-when given succinycholine

34

G6PD deficiency

produces NADPH - which produces glutathione
-oxidative damage leads to hemolytic anemia

35

clinical testing

preclinical - animals
phase 1 - small group - pharmacokinetics
phase 2 - single blind - efficacy, dosing
phase 3 - double blind - continued drug efficacy
phase 4 - continued monitoring, large number of patients

phase 0 - microdosing

36

chronic toxicity

6 months

37

subacute toxicity

2 weeks to 3 months

38

carcinogenic potential

2 year, two species

39

open label

both know

40

NDA

after phase 3

41

CYP2D

slow, normal, or ultrafast metabolizer phenotypes

42

codeine

to morphine
-CYP2D6
-variation in this enzyme with 3 phenotypes

43

VKORC1

genetic variation in warfarin therapy

44

CYP2C9

genetic variation in warfarin therapy